Shanghai Medicilon Inc.

  Recently, Xuanzhu Biopharmaceutical (Xuanzhu) and its wholly-owned subsidiary Beijing Xuanzhu Bio, obtained clinical trial approval for the double-antibody ADC drug KM501 (No.: 2023LP00278).  This product is suitable for the treatment of advanced/metastatic solid tumors with positive/expression, amplification or mutation of HER2, including related advanced tumors with low expression of HER2.  The drug is the world's first double-antibody ADC drug that completely knocks out fucose, and is expected to become the "Best in Class" drug. Shanghai Medicilon Inc. (Medicilon), as a partner of Xuanzhu, provided KM501 with GLP-compliant preclinical research services based on the Medicilon Antibody Development Service Platform, including pharmacokinetic studies and  safety evaluation . This has won time for Xuanzhu to advance the KM501 into clinical research as fast as possible. Medicilon Antibody Drug Conjugate (ADC) R&D Service Platform The whole process facilitates the ...

  March 17, 2023 Table of Contents 1. Doxorubicin (DOX) 2. Nanodiamonds (NDs) 3. Nanodiamond-Doxorubicin complexes (ND-DOX) 4. Naïve Beagle Dog 5. Using Naïve Beagle dogs to evaluate the safety of nanodiamond drug delivery platform to deliver DOX. 6. Conclusions Nanodiamond-Doxorubicin complexes refer to a drug delivery system where tiny diamond particles, called nanodiamonds, deliver a chemotherapy drug called Doxorubicin to cancer cells. Research into nanodiamond-Doxorubicin complexes is ongoing, and early studies have shown promising results. However, more research is needed to fully understand the safety and effectiveness of this drug delivery system before it can be used in clinical settings.Naive Beagle Dogs(Naïve Beagle Dogs) are popular dogs. They are often used in scientific research for various purposes, including drug development, behavior studies, and genetics research. This blog will discuss the safety evaluation of Nanodiamond-Doxorubicin Complexes in a Naive Beagle D...